BioPharma Dive4d
Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Gene therapy for rare epilepsy shows promise in mice
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
GlobalData on MSN4d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
News Medical on MSN8d
Gene therapy shows promise in treating SCN1B-linked epileptic encephalopathies
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...
BioSpace4d
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
technologynetworks5d
Epilepsy Gene Therapy Reduces Seizures and Prolongs Lifespan in Mice
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
A new gene therapy for children with Dravet syndrome developed
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
Science Daily9d
Gene therapy for rare epilepsy shows promise in mice
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy. Dravet syndrome and other developmental epileptic encephalopathies ...